Highlights in gi oncology 2023

March 3rd - 4th (Hybrid Event)

Rosen Shingle Creek Hotel

Welcome Back to Highlights in GI Oncology!

A GI Oncology Conference for Oncology Clinicians

Highlights in GI Oncology is a conference designed to provide the latest science and education from the world’s premier GI oncology event, the ASCO Gastrointestinal Cancers Symposium. The abstracts selected for presentation and discussion reflect the foremost research and strategies in oncology that will impact clinical practice and patient care.

The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in GI cancer treatment. Expert faculty will review the findings, discuss the results potential impact on the current standard of care, and apply the results within the clinical context of a patient case.

Presented By:

REGISTER TODAY

 Register early to guarantee your spot! This is a hybrid event. Attend in-person or online.

 DesignationEarly Bird AdvancedGeneral Registration
Deadline Dec. 3, 2022Deadline Feb. 3, 2023Deadline Mar. 3, 2023
Physicians$115$145$190
Pharmacists$65$95$130
NPs, PAs, RNs, & others$50$80$115
Pharma / Med Device Company Employee**$190$225$260
Students & Fellows*Free*

  • Industry Employee** registration is location-based pricing +$200

*Student is defined as currently enrolled in an advanced learning institution and/or studying in order to enter a particular profession. If you would like to attend as a Student, please contact info@horizoncme.com for further information.

**Defined as anyone employed by a drug, device, or diagnostic company. The primary goal of the conference is to educate practicing clinicians on the latest advances and strategies in the care of cancer patients. Because space is limited and to ensure sufficient seats are available for clinicians, Industry Employees may register as an attendee only if you have a clinical title (NP, PharmD, MD, PA, etc.). 

Cancellation Policy: Fees are non-refundable and non-transferable.

Conference Planning Committee

Faculty Speakers

Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK), Professor of Medicine at Weill Medical School at Cornell University, and Adjunct Professor at Trinity College Dublin in Dublin, Ireland. Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC). Professor Abou-Alfa is the immediate previous Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force and currently serves at the NCI AIDS Malignancy Consortium (AMC) Vice-Chair for Solid Tumor Working Group, while serving on its Steering Committee. Professor Abou-Alfa is a member of the International Affairs Committee of the American Society of Clinical Oncology (ASCO) and serves as member of its Steering Committee. Professor Abou-Alfa is also the immediate previous President for the International Society of Gastrointestinal Oncology (ISGIO). Professor Abou-Alfa serves on the council of the governing board of the Asia Pacific Primary Liver Cancer Expert Association Professor Abou-Alfa majored in biology, earned his medical degree, and now serves as a trustee on the Board of Trustees of his alma mater the American University in Beirut (AUB). Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, received his MBA from Columbia University, and is completing his JD from Fordham University.

Professor Abou-Alfa’s research focuses on incorporating small biological molecules and checkpoint inhibitors into standard cancer therapies. In recent years, his group at MSK led the first efforts evaluating sorafenib in HCC, that was ultimately approved by the FDA for that indication in 2007. Professor Abou-Alfa also led his group at MSK on the efforts evaluating cabozantinib which was approved by the FDA for HCC indication in 2019. Professor Abou-Alfa has also championed key work in determining novel targeted therapies for IHC and GB, targeting IDH-1, FGR-2, and Her-2. He lately led the efforts of pemigatinib, which was approved by the FDA in 2020, for patients with IHC and FGFR-2 alterations, and ivosidenib which was approved by the FDA in 2021, for patients with IHC and IDH1mutaiton. 

He also collaboratively and part of a team effort helped with the FDA approval of infigratinib, which was approved by the FDA in 2021, for patients with IHC and FGFR-2 alterations. With his heavy involvement the use of checkpoint inhibitors in the malignancies of interest, Professor Abou-Alfa led the effort of positive outcome dual immunotherapy of durvalumab plus tremelimumab the HIMALAYA study worldwide. This adds to a global effort to be understand the tumor immune microenvironment (TIME) that would help identify the most applicable therapeutics or combination of. He also continues to work on determining the right CAR-T antigens for HCC and FLC, and IHC. Professor Abou-Alfa and team have also worked and were first to report on germline alterations associated with biliary tract cancers.

Professor Abou-Alfa envisions the universal quest for health, embodied by physicians upholding humanistic ideals, supersedes geopolitics among the world’s people. In recognition of his medical, humanitarian and social efforts, Professor Abou-Alfa is bestowed the Order of Merit, Captain, National Order of the Cedar by the Presidency of the Government of the Lebanese Republic. Recognizing germline alterations as an endless opportunity to explore cancer related environmental and other genetic risk factors of varied populations and regions, Professor Abou-Alfa co-led a global effort to study humanity cancer germline and environmental convergence and divergence cancer predispositions worldwide. Professor Abou-Alfa strongly advocates for greater awareness of cancer’s global impact; and continues to lead several international educational and research efforts with different institutions worldwide. Professor Abou-Alfa spearheaded many projects worldwide including the MENA region, Africa, Southeast Asia,
Eurasia, and the Americas. These efforts include several monthly video-link worldwide educational conferences led by MSK, which is now global and includes institutions from throughout the global, including add to Lebanon, India, Saudi Arabia, United Arab Emirates, Malawi, and Brazil, with several of its proceedings are already published in peer–reviewed journals. 

Professor Abou-Alfa also leads regular class-training conferences offered on competitive basis worldwide in collaboration between MSK and AUB to help educate and teach about the state of the art of cancer care and learn about the germline, somatic, and environmental risk factors and treatment practices in the respective country and region. This almost two decades old collaboration, one of the most sustained between an US institution and one in the MENA region, has led to the development of the first joint tissue bank with a shared database in the region. The joint programs also offer supported post-graduate training opportunities for excelling medical graduates. Collectively, these collaborative efforts Professor Abou-Alfa develop the business model that helps enhance academic interaction and set a platform to build on partnerships among institutions. Along the same path, Professor Abou-Alfa is leading an effort along with colleagues from 23 countries in Africa to draft the Africa Guidelines for screening and treating HCC, written by African colleagues for Africa.

Professor Abou-Alfa also takes on an advocacy role while research funding continue to lag despite the worldwide impact of this disease. Professor Abou-Alfa serves and served on several advisory boards including the American Liver Foundation, Fibrolamellar Carcinoma Foundation, Cholangiocarcinoma Foundation, and Blue Faery Foundation, and is a regular volunteering contributor to the Binay Foundation in Nepal. He co-authored with Professor Ronald DeMatteo 100 Questions and Answers About Liver Cancer, now coming to its fourth edition, and with his dear wife and colleague Professor Eileen O’Reilly, also a medical oncologist at MSK, 100 Questions and Answers About Biliary Cancer now coming to its third edition.

Dr. Aman Chauhan earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects.

His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee.

Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society.

Dr. Kristen Ciombor is an Associate Professor in the Division of Hematology/Oncology within the Department of Internal Medicine at the Vanderbilt University Medical Center. She received her medical degree from the University of Miami Miller School of Medicine in Miami, FL. She completed her internal medicine residency and chief residency at the University of Miami/Jackson Medical Center/Miami VA Medical Center. She then completed her fellowship in hematology/oncology at Vanderbilt, where she also graduated with a Master’s of Science in Clinical Investigation. Prior to joining the Vanderbilt faculty in 2017, Dr. Ciombor was Assistant Professor of Internal Medicine in the Division of Medical Oncology at the Ohio State University. 

A board-certified medical oncologist, Dr. Ciombor specializes in the treatment of patients with gastrointestinal cancers. Her research involves the design and implementation of clinical trials for GI malignancies, and colorectal cancer in particular. She also has a research interest in the genomics of colorectal cancer and translational medicine, and she leads multiple national investigator-initiated clinical trials in this space. 

She is a project co-leader of the Vanderbilt-Ingram Cancer Center’s (VICC) Gastrointestinal Specialized Program of Research Excellence (GI SPORE), co-leader of the Vanderbilt-Ingram Cancer Center’s Translational Research and Interventional Oncology Program, and the Eastern Cooperative Oncology Group (ECOG)’s Colorectal/Anal Working Group chair. Dr. Ciombor is also a member of the NCI Rectal/Anal Cancer Task Force, the National Comprehensive Cancer Network’s (NCCN) Colorectal/Anal/Small Bowel Guidelines Panel, the International Rare Cancers Initiative (IRCI) Anal Cancer Working Group, the Academic GI Cancer Consortium (AGICC), the Colorectal Cancer Alliance Biomarker Think Tank Advisory Committee, and the Academic and Community Cancer Research United (ACCRU), of which she serves on the board of directors.

Cathy Eng is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of the new Young Adults Cancers Program, and the Chair, Developmental Research Program for the GI SPORE, at the Vanderbilt-Ingram Cancer Center. She served as the Ambassador for the American Cancer Society ResearcHERS campaign in Nashville (2020-2022). She is currently the Director for Strategic Relations for Vanderbilt-Ingram Cancer Center. She has served on the Scientific Review Committee and remains on the Clinical Trials Shared Resource Oversite Committee. She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves as a Professional Development Mentor. She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng has also been highly active serving on ASCO, ECOG, and SWOG. She has served on multiple committees for ASCO including the Career Development Committee, Education Committee for Colorectal Cancer; ASCO Scientific Program Committee Track Leader for the Gastrointestinal Cancer-Colorectal/Liver Track and served on the Steering Committee 2012-2015. She is the former Chairman of the Scientific Program Committee of the ASCO Gastrointestinal Cancer Symposium from 2012-2013 and Chairman, Steering Committee, GI Cancers Symposium 2016. She was chosen for the ASCO Leadership Development Program and served on the ASCO Government Relations Committee; worked with the ASCO Cancer Prevention Committee on the consensus statement regarding HPV vaccination; served on the ASCO Nausea and Vomiting Guidelines Committee, ASCO Taxonomy Task Force, ASCO Social Media Committee, and is currently on the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee.

She was the co-chair of the SWOG Rectal/Anal Cancer Subcommittee and was the Vice-Chair for the SWOG GI Committee. She was the Chairman of the NCI Rectal/Anal Task Force (two terms), served on the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee. She has published in many peer-reviewed journals including Journal of Clinical Oncology, Lancet Oncology, Nature Review, JNCI, Annals of Oncology, Cancer, and Annals of Surgical Oncology. She has previously received an NCI grant “Administrative Supplements to the institutional CCSG grant to Support Biomarker Studies Associated with NCI-supported Clinical Trials of Immunotherapy”. She was a co-PI for the MD Anderson Moonshot for HPV-Associated Malignancies (Section Lead for the Rare Cancers subsection) and continues to serve as a grant reviewer on the MD Anderson Colorectal Cancer Moonshot Grant and the Sabine award. She has served as a consultant to the FDA and AHRQ, Cancer Research UK: Training & Career Development Board – Clinician Scientist Fellowship, the Italian Association for Cancer Research, the Dutch Digestive Foundation, the Stand Up to Cancer (SU2C) – Farrah Fawcett Foundation Joint Scientific Advisory Committee (JSAC) and the SWOG Impact Award.

Dr. Sarah Hoffe is the Section Head of GI Radiation Oncology at Moffitt Cancer Center.  She is a Senior Member at Moffitt and joined the faculty 16 years ago. Dr. Hoffe’s research and clinical interests include cancers of the esophagus, stomach, liver, pancreas, bile duct, rectum, colon, anus, as well as neuroendocrine cancers. She has extensive experience with MRI guided radiation therapy for GI cancers.  Dr. Hoffe is also interested in the integration of novel digital health technologies that will improve the patient experience, such as piloting novel virtual reality tools in the clinic and developing 360 videos to enhance the new patient journey for which she has won 27 Telly Awards.  She serves as the Director of Radiation Oncology Virtual Reality and Innovation.  In addition, she has an academic interest in professional development and has created many educational sessions focusing on leadership training at national meetings such as ASTRO.  At Moffitt, she is the director of the Radiation Oncology resident leadership class and multidisciplinary leadership journal club.
 
After completing her undergraduate studies at Brown University, Dr. Hoffe received her MD degree from the University of Vermont.  She then completed a transitional year internship at Mayo Clinic Jacksonville followed by residency in radiation oncology at Duke University Medical Center and Memorial Sloan-Kettering Cancer Center and fellowship at MD Anderson Cancer Center.   Dr. Hoffe devotes a significant portion of her time to the promotion of medical education.  She is also very involved in the education of physicians in training at Moffitt.   In 2009, Dr. Hoffe was the first radiation oncologist at Moffitt to be selected as the Physician of the Year and has twice been selected as the Moffitt Clinical Mentor of the Year.

Dr. Milind Javle is a Professor of GI Medical Oncology at MD Anderson Cancer Center, Houston, Texas where he leads the Biliary Cancer Program. He graduated from Grant Medical College in India, did his residency at SUNY Buffalo and Oncology Fellowship at Roswell Park Cancer Center, where he specialized in GI Cancers. He has been at MD Anderson since 2007 and has built a reputation as a leader in GI Oncology, particularly biliary and pancreatic cancers. He has over 200 publications in the field, has extensive research support from NIH, Foundations, Industry and Philanthropy. He is the current Chair of the NCI Task Force in Hepatobiliary Cancers, the former Chair of the International Cholangiocarcinoma Research Network, Vice President of the Cholangiocarcinoma Foundation and Co-Chair of the SWOG Hepatobiliary Committee along with leadership roles at MD Anderson. 

Dr. John RT Monson is the Executive Medical Director of Colorectal Surgery and the DigestiveHealth Institute and Surgery Institute at AdventHealth, Central Florida. He is also a Professor of
Surgery at the Loma Linda Medical School, Florida State University and University of Central
Florida, College of Medicine. Dr. Monson is a colon and rectal surgeon and fellowship trained in
surgical oncology, vascular surgery and colon and rectal surgery. He is the founder of and serves
as Clinical Director of the Surgical Health Outcomes Consortium (SHOC) at AdventHealth,
Orlando.

Prior to moving to Orlando, Dr. Monson became Chief of the University of Rochester, School of
Medicine Division of Colorectal Surgery and Vice Chair of its Department of Surgery in 2008.
He was also the founder and Director of the Surgical Health Outcomes and Research Enterprise
(SHORE) as well as Vice-Chairman for Research.

Dr. Monson, who was born in Dublin, Ireland, served as a Professor of Surgery, Head of the
Academic Surgical Unit, and Deputy Head of the School of Medicine at the University of Hull in
England between 1993 and 2008 before relocating to Rochester, New York.

Dr. Monson, whose areas of expertise include the use of minimally invasive technologies in
colorectal cancer treatment including Transanal Endoscopic Microsurgery (TEMS), laparoscopy
and robotic surgery. Dr. Monson has been involved in basic research into a broad range of
cancer-related areas and qualitative assessments of decision-making in cancer care.
Dr. Monson is a Fellow of the American Society of Colon and Rectal Surgeons and served as the
Chair of the ASCRS Research Committee and a member of the Foundation Board for six years.
He is also currently a member of the IBD and International Committees having previously served
on the Membership, Rectal Cancer Cor-ordinating, Standards and Public Relations Committees
as well as the Executive Council. He is a Co-Editor for Diseases of Colon and Rectum and
Digestive Surgery and serves on multiple editorial boards including Annals of Surgery and the
Journal of Gastrointestinal Surgery. He is a Fellow of all Four Royal Colleges of Surgeons in the
British Isles (and Honorary Fellow of three) and is an Honorary Fellow of the ASGBI and the
Society of University Surgeons.

He has published almost 400 scientific papers and 5 books. His current research continues to
focus on health care delivery and the implementation of change within health care systems with a particular emphasis on cancer care. In addition, he serves on the Executive Committee of the
National Accreditation Program for Rectal Cancer having completed two terms as a member of
the Commission on Cancer.

Eileen M. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the Section Head for Hepatopancreaticobiliary/ Neuroendocrine Cancers, Gastrointestinal Oncology Service, Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer and is an Attending Physician and Member at MSK and Professor of Medicine at Weill Cornell Medical College. Dr. O’Reilly received her medical degree at Trinity College in Ireland. She completed her postgraduate training in Ireland and subsequent Hematology/Oncology Fellowship training at MSK.

 Dr. O’Reilly is a clinical scientist whose research focus involves integration of molecular and genetic-based therapies for pancreas cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr. O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr. O’Reilly is the Principal Investigator of multiple phase I, II, III trials in pancreas cancer and has authored/co-authored > 375 articles, editorials, and book chapters and has a H-index of 89. She serves as an Associate Editor for the Journal of Clinical Oncology and Senior Editor for several other journals and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), NIH, DOD, and various international entities. She is the PI of the MSK Pancreas Specialized Program in Oncology Research Excellence (SPORE), an NCI funded team science grant. Dr. O’Reilly is the recipient of numerous awards including the Burkitt Medal (TCD) in 2022, and Giants of Cancer Care GI Oncology, 2023. 

Dr. O’Reilly’s other responsibilities include Chair of the Human Research Protection Program and Institutional Review & Privacy Board (IRB). Nationally, Dr. O’Reilly is Co-Chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC), and serves in leadership roles in several advocacy organizations including National Pancreas Foundation and Pancreas Cancer Action Network.

Dr. Philip is the head of the Gastrointestinal and Neuroendocrine Multidisciplinary Team at the Henry Ford Cancer Institute in Detroit. He is a Professor of Oncology and Pharmacology at Wayne State University School of Medicine.  Additionally, he is co-leader of the Pancreas Cancer Program.  He chairs the GI Committee at the national cooperative research group SWOG. Dr. Philip earned his medical degree at the University of Baghdad College of Medicine in Iraq and his Ph.D. in Clinical Pharmacology and Pharmacogenetics at the University of London Guy’s Hospital Medical School in the United Kingdom. He completed a fellowship in Medical Oncology at the University of Oxford and M.D. Anderson Cancer Center in Houston. He is board certified in Medical Oncology in the United States and a Fellow of the Royal College of Physicians in the United Kingdom. 

His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a major focus on pancreatic cancer.   He has been a principal investigator on clinical trials in pancreatic and other GI cancers. Dr. Philip has authored more than 250 manuscripts, review articles and editorials and co-edited a book on pancreatic cancer and another on gastrointestinal cancers. Dr. Philip is a member of the scientific advisory boards of the Pancreatic Cancer Action Network and the Sky Foundation in addition to various advisory roles with pharmaceutical companies. He is a member of ASCO, AACR, and ESMO.

Dr. Jose M. Pimiento is a Surgical Oncologist from the GI Oncology program at the H. Lee Moffitt Cancer Center, where he is the Medical Director if the Inpatient Surgical service and the leader of the Gastroesophageal Oncology section.  His area of clinical and translational research is in foregut cancers including gastric, esophageal and pancreatic malignancies, with special interest in chemoprevention strategies, nutritional support of patients with gastrointestinal malignancies and minimally invasive techniques for gastrointestinal malignancies.

Dr. Scott is an Associate Professor of Medicine, Co-Lead of Clinical and Translational Oncology Program (CTOP), Co-Lead of GI Oncology Clinical Research Team (CRT), Phase 1/Early Therapeutics team member, and GI medical oncologist who specializes in clinical and translational research in colorectal cancer. Dr. Scott is a practicing medical oncologist with a robust patient volume at UACC. Dr. Scott is an accomplished clinical investigator and has been Principal Investigator of over 16 colorectal cancer trials including Phase 1 studies, developed and led IITs including a positive Phase 2 study, and has been recognized as a key opinion leader in GI malignancies. As the top investigator for accruals for the Phase 1 trial entitled, “A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors.”

 Dr. Scott is one of the most experienced investigators with the CLK/DYRK inhibitor SM08502 (Cirtuvuvint). Based on this, he gave a podium presentation at the European Society of Medical Oncology (EMSO) Annual Meeting 2022 entitled, “Preliminary Evidence of Clinical Activity from Phase 1 and 1b Trials of the CLK/DYRK Inhibitor Cirtuvivint (CIRT) in Subjects with Advanced Solid Tumors.” Dr. Scott also has a collaborative partnership with Dr. Jianqin Lu and has authored publications in Nature Nanotechnology for the work in combining immunogenic co-delivery nanotherapeutics for synergizing immune checkpoint blockade therapy in CRC. Based on this work, He is also a Co-Investigator of Dr. Lu’s NCI funded R01 entitled, “A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy”. Dr. Scott also serves on the NCI Hepatobiliary Task Force and is currently Co-Chair for the ASCO Expert Panel for “Neoadjuvant Management for Rectal Cancer.”

Dr. Ravi Shridhar is a board-certified radiation oncologist who specializes in the treatment of gastrointestinal malignancies. He is involved with the treatment of esophageal, gastric, small intestinal, colorectal, anal, pancreaticobiliary and hepatic malignancies (primary and secondary). Dr. Shridhar oversees radiation oncology for the treatment of GI cancers at Advent Health. He has been instrumental in leading and overseeing treatment programs of Y90 for liver cancer and metastases and Lutathera for the treatment of neuroendocrine carcinomas. He is the radiation oncology representative for the rectal cancer program as part of accreditation by the American College of Surgeons and Commission on Cancer.

Jason Starr is an oncologist in the Department of Internal Medicine at Mayo Clinic hospital in Jacksonville, Florida. He specializes in gastrointestinal (GI) malignancies and treats conditions such as: neuroendocrine tumors (NETs); neuroendocrine carcinoma (NEC); colon cancer; esophageal cancer; liver cancer; pancreatic cancer, and stomach cancer. Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship.

Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology. “The greatest joy of my career is the interaction and relationships I am able to have with my patients,” says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief. Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic’s conviction to hope, faith, and science.

Dr. Stacey Stein is a medical oncologist, focusing on GI cancers. She has been the Yale site Principal Investigator for multiple clinical trials including both Pharmaceutically sponsored and Southwest Oncology Cooperative Group studies. Dr. Stein is a PI for a multicenter trial at Yale, examining the role of anetumab in advanced pancreatic cancer. Her initial work focused on studying the role of homeobox proteins in developmental biology. Dr. Stein’s clinical work has focused on clinical trials in oncology. Her focus in fellowship was in breast and ovarian cancer, developing and analyzing novel chemotherapy combinations. Dr. Stein’s current focus has been in developing trials for patients with GI malignancies. She has participated in several studies at Yale and written review articles with colleagues.

Course Overview

Highlights in GI Oncology is a conference designed to provide the latest science and education from the world’s premier GI oncology event, the ASCO Gastrointestinal Cancers Symposium. The abstracts selected for presentation and discussion reflect the foremost research and strategies in oncology that will impact clinical practice and patient care.

The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in GI cancer treatment. Expert faculty will review the findings, discuss the results potential impact on the current standard of care, and apply the results within the clinical context of a patient case.

Intended Learners

This CME initiative is designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with GI cancers.  

"This was a very informative conference that provided a good review of issues in GI oncology as well as introducing some new information"

"Great speakers all very knowledgeable in their fields"

"Great meeting from start to finish. Plenty of networking time, along with great education for precise patient care"

Accommodations

We want to ensure that your time at the Highlights in GI Oncology 2024 conference is convenient and memorable. Staying at our host hotel provides a hassle-free experience and puts you at the heart of the activity surrounding the conference.

Booking Deadline: January 23, 2024

Room rates: TBD

Dates for discounted rates: TBD

Parking: 28 USD for self-parking | 40 USD for valet parking (plus tax, subject to change)

Resort Fees: TBD

Disclaimer:
All reservations must be booked using the link above before the closing date listed. Overnight accommodation, parking, and resort fees will revert back to standard hotel pricing outside of the dates above. A set number of rooms have been blocked off for the discounted pricing. If all of those rooms have already been booked, discounted pricing may not be available for additional rooms or accommodations.

Click here to book your room today!